News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,120 Results
Type
Article (39783)
Company Profile (249)
Press Release (659088)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204237)
Career Advice (2007)
Deals (35423)
Drug Delivery (95)
Drug Development (81080)
Employer Resources (172)
FDA (16181)
Job Trends (14858)
News (345282)
Policy (32540)
Tag
Academia (2561)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49474)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16186)
Artificial intelligence (253)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11638)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (177)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2257)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (151)
Cell therapy (424)
Cervical cancer (19)
Clinical research (66004)
Collaboration (835)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2205)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86632)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112423)
Executive appointments (722)
FDA (17443)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (747)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (709)
Government (4417)
Grass and pollen (4)
Guidances (67)
Healthcare (18820)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16508)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13377)
Medtech (13382)
Mergers & acquisitions (19459)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6515)
Non-profit (4481)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57315)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20573)
Phase II (29064)
Phase III (21651)
Pipeline (1204)
Policy (139)
Postmarket research (2563)
Preclinical (8749)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5909)
Recruiting (65)
Regulatory (22282)
Reports (46)
Research institute (2331)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3581)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (688)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (143)
Last 7 days (899)
Last 30 days (2597)
Last 365 days (32765)
2025 (10702)
2024 (35229)
2023 (40085)
2022 (51197)
2021 (55719)
2020 (54100)
2019 (46550)
2018 (35033)
2017 (32127)
2016 (31500)
2015 (37569)
2014 (31334)
2013 (26375)
2012 (28592)
2011 (29279)
2010 (27352)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37874)
Australia (6193)
California (6126)
Canada (2013)
China (523)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81305)
Florida (911)
Georgia (207)
Idaho (57)
Illinois (535)
India (25)
Indiana (307)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4569)
Michigan (220)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1726)
New Mexico (28)
New York (1746)
North Carolina (966)
North Dakota (8)
Northern California (2680)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1378)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2299)
Tennessee (101)
Texas (906)
United States (23111)
Utah (180)
Virginia (145)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (54)
699,120 Results for "pluri inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
April 10, 2025
·
8 min read
Business
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
Pluri Inc. announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.
March 6, 2024
·
6 min read
Press Releases
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
November 12, 2024
·
1 min read
Policy
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
Pluri Inc., a leading biotechnology company that transforms cells into solutions, announced the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023.
June 6, 2024
·
7 min read
Pluri Inc. Announces 1-for-8 Reverse Share Split
Pluri Inc. announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024.
March 27, 2024
·
4 min read
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
Leading biotechnology company Pluri Inc. issued the following update from CEO and President, Yaky Yanay.
February 28, 2024
·
10 min read
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced leadership from its business verticals will be presenting at, and participating in, the following conferences.
March 28, 2024
·
5 min read
Engage with Pluri’s Talent: Exciting Conference Appearances Ahead
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced its participation in the following upcoming conferences.
March 19, 2024
·
2 min read
Press Releases
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
February 5, 2025
·
6 min read
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Pluri Inc., a leading biotechnology company that transforms cells into solutions, launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors – a significant medical need which currently lacks effective treatments.
May 2, 2024
·
8 min read
1 of 69,912
Next
